| COVID-19 |
1 |
1 |
| Acute Respiratory Distress Syndrome |
0 |
0.57 |
| Pandemic |
0 |
0.56 |
| Severe Acute Respiratory Syndrome |
0 |
0.49 |
| Virology |
0 |
0.95 |
| Genomic Medicine |
0 |
0.45 |
| Bacteria |
0 |
0.28 |
| Cancer |
0 |
0.21 |
| Antibiotics |
0 |
0.16 |
| Vaccines |
0 |
0.16 |
| Fellowship |
0 |
0.14 |
| Dermatitis |
0 |
0.08 |
| Revenue and Practice Management |
0 |
0.08 |
| Connecticut |
0 |
0.07 |
| Dorsum |
0 |
0.07 |
| Epidemiology |
0 |
0.07 |
| Europe |
0 |
0.07 |
| Hand |
0 |
0.07 |
| Id Reaction |
0 |
0.07 |
| Information Theory |
0 |
0.07 |
| Investment |
0 |
0.07 |
| Peer Review |
0 |
0.07 |
| Professional Practice |
0 |
0.07 |
| Receptors |
0 |
0.07 |